Today, the Centers for Disease Control and Prevention made its formal recommendations for the use of Shingrix—a new vaccine that appears to offer significantly better protection against shingles ...

In its just-released World Preview report, ... The analysts expect shingles vaccine Shingrix—which GSK submitted to U.S. and European authorities last year—to climb to $1.126 billion that year.

RELATED: GlaxoSmithKline's Shingrix supply will vault upward, CEO says—in 2024, that is After its 2017 launch, Shingrix sales climbed to £1.8 billion last year, representing one of the drug ...